Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effects of endogenous GIP in patients with type 2 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mechanisms in Endocrinology: FXR signalling - a novel target in metabolic diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exendin(9-39)NH2 - recommendations for clinical use based on a systematic literature review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Objective: The insulinotropic effect of exogenous, intravenously infused glucose-dependent insulinotropic polypeptide (GIP) is impaired in patients with type 2 diabetes. We evaluated the effects of endogenous GIP in relation to glucose and bone metabolism in patients with type 2 diabetes using a selective GIP receptor antagonist and hypothesized that the effects of endogenous GIP were preserved.

Design: A randomized, double-blinded, placebo-controlled, crossover study.

Methods: Ten patients with overweight/obesity and type 2 diabetes (mean±s.d.; HbA1c 52 ± 11 mmol/mol; BMI 32.5 ± 4.8 kg/m2) were included. We infused a selective GIP receptor antagonist, GIP(3-30)NH2 (1200 pmol/kg/min), or placebo (saline) during two separate, 230-min, standardized, liquid mixed meal tests followed by a meal ad libitum. Subcutaneous adipose tissue biopsies were analyzed.

Results: Compared with placebo, GIP(3-30)NH2 reduced postprandial insulin secretion (Δbaseline-subtracted area under the curve (bsAUC)C-peptide% ± s.e.m.; -14 ± 6%, P = 0.021) and peak glucagon (Δ% ± s.e.m.; -11 ± 6%, P = 0.046) but had no effect on plasma glucose (P = 0.692). Suppression of bone resorption (assessed by circulating carboxy-terminal collagen crosslinks (CTX)) was impaired during GIP(3-30)NH2 infusion compared with placebo (ΔbsAUCCTX; ±s.e.m.; -4.9 ± 2 ng/mL × min, P = 0.005) corresponding to a ~50% reduction. Compared with placebo, GIP(3-30)NH2 did not affect plasma lipids, meal consumption ad libitum or adipose tissue triglyceride content.

Conclusions: Using a selective GIP receptor antagonist during a meal, we show that endogenous GIP increases postprandial insulin secretion with little effect on postprandial glycaemia but is important for postprandial bone homeostasis in patients with type 2 diabetes.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind185
Udgave nummer1
Sider (fra-til)33-45
Antal sider13
ISSN0804-4643
DOI
StatusUdgivet - 21 maj 2021

ID: 65747238